Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof
AssigneeKojin Therapeutics, Inc.
InventorsVasanthi Viswanathan, Priya Chatterji
Life of this patent
Estimating the term…
Abstract
Methods and systems and compounds and compositions for the modulation or regulation of weight and/or inducing weight loss and other diseases and conditions in a subject are provided. Various methods of administration are described for modulation or regulation or induction of weight loss and other diseases and conditions are provided. Additionally, methods of weight loss and methods for the treatment of obesity, for example by the modulation of one or more enzymes in the ferroptosis pathway, are provided.
Claims137
A method of inducing weight loss, fat loss, or both, in a subject, the method comprising administering to the subject a ferroptosis inducing agent in an amount sufficient to induce the weight loss, the fat loss, or both.
A method of inducing, regulating, or modulating weight loss, body composition, or fat loss or fat reduction in a subject, the method comprising administering to the subject a therapeutically effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof to the subject, thereby inducing, regulating, or modulating the weight loss, body composition, or fat loss or fat reduction in the subject.
The method of any preceding claim, wherein the subject is administered concurrently or consecutively an additional agent or therapy.
The method of any preceding claim, wherein the subject has not been diagnosed with a cancer.
The method of any preceding claim, wherein the subject is a subject in need thereof.
The method of any preceding claim, wherein the subject has diabetes type I, diabetes type II, diabetes type IIIa, or a metabolic syndrome.
A composition comprising i) a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL;
- and ii) a GLP-1 agonist or a salt thereof, a gastric inhibitory polypeptide analog, a naltrexone-bupropion or a salt thereof, an orlistat or a salt thereof, a phentermine or a salt thereof, and a phentermine-topiramate or a salt thereof, or a selenium or a salt thereof.
A composition comprising i) a glutamate-cysteine ligase (GCL) modulating agent, and ii) a GLP-1 agonist or a salt thereof, a gastric inhibitory polypeptide analog, a naltrexone-bupropion or a salt thereof, an orlistat or a salt thereof, a phentermine or a salt thereof, and a phentermine-topiramate or a salt thereof, or a selenium or a salt thereof.
A method of modulating iron metabolism in a plurality of cells in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-inducing agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby modulating the iron metabolism in the subject and thereby inducing ferroptosis in the subject.
A method of modulating iron metabolism in a plurality of cells in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-inducing agent, thereby modulating the iron metabolism in the subject.
A method of treating, inducing, regulating, or modulating iron metabolism or a disease or condition associated with iron metabolism in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby treating, inducing, regulating, or modulating the iron metabolism or the disease or condition associated with the iron metabolism in the subject.
A method of modulating cholesterol metabolism in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby modulating cholesterol metabolism in the subject.
A method of modulating cholesterol metabolism in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-inducing agent, thereby modulating the cholesterol metabolism in the subject.
A method of treating, inducing, regulating, modulating, or diminishing cholesterol metabolism or a disease associated with cholesterol metabolism in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby treating, inducing, regulating, modulating, or diminishing the cholesterol metabolism or the disease or condition associated with the cholesterol metabolism in the subject.
A method of treating, inducing, regulating, modulating, diminishing, or increasing a reactive oxygen species or a disease or condition associated with a reactive oxygen species in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby treating, inducing, regulating, modulating, diminishing, or increasing the reactive oxygen species or the disease or condition associated with the reactive oxygen species in the subject.
A method of increasing a reactive oxygen species in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby increasing the reactive oxygen species in the subject.
A method of promoting at least one of:
- treating, surviving, modulating, or diminishing an acute stress;
- a chronic stress response;
- an immune hypersensitivity;
- cachexia;
- kidney disease;
- neurodegeneration;
- cardiotoxicity;
- or cardiotoxicity caused at least in part by chemotherapy;
- in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby treating, inducing, regulating, modulating, diminishing, or increasing the acute stress;
- a chronic stress response;
- an immune hypersensitivity;
- cachexia;
- kidney disease;
- neurodegeneration;
- cardiotoxicity;
- or cardiotoxicity cause at least in part by chemotherapy in the subject.
A method of promoting at least one of:
- treating a kidney disease in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL, or any combination thereof, thereby treating the kidney disease in the subject.
A method of promoting at least one of:
- treating a kidney disease in a subject, the method comprising administering to the subject a therapeutically effective amount or an effective amount of a ferroptosis-inducing agent, thereby treating the kidney disease in the subject.
The method of any preceding claim, wherein the agent is a compound or a salt thereof in Table 1.
The method of any preceding claim, wherein the agent is in the form of a pharmaceutical composition that further comprises a pharmaceutically acceptable:
- carrier, excipient, or diluent.
A composition comprising i) a ferroptosis-modulating agent, a glutamate-cysteine ligase (GCL) modulating agent, an agent that binds to GCL, an agent that inhibits GCL;
- and ii) a GLP-1 agonist or a salt thereof, a gastric inhibitory polypeptide analog, a naltrexone-bupropion or a salt thereof, an orlistat or a salt thereof, a phentermine or a salt thereof, and a phentermine-topiramate or a salt thereof, or a selenium or a salt thereof.
Dependencies are inferred from the claim text.